26 articles
The UK's NICE has approved AstraZeneca and Daiichi Sankyo's breast cancer drug Enhertu for NHS use in England, expanding access to approximately 1,000 patients annually following revised cost-effectiv
AstraZeneca CEO Pascal Soriot faces scrutiny over rejecting a deal, maintaining a long-term R&D strategy over short-term acquisitions while targeting $80bn revenue by 2030.
AstraZeneca and Bristol Myers Squibb denied merger talks, dispelling rumors of a $400 billion deal that previously caused significant share price movements.
Investors are shifting capital into U.S. healthcare stocks, driving the S&P 500 healthcare index to record highs amid rising M&A activity and strong earnings forecasts from major drugmakers like AbbVi
An editorial advises AstraZeneca against a proposed $400bn merger with Bristol Myers Squibb, recommending it stick to its organic growth strategy rather than high-risk financial engineering. Concerns
Gulf chemical manufacturers continue operations despite regional conflicts, while Bristol Myers Squibb and AstraZeneca are reportedly exploring a merger.
Japan and the US executed a historic $60 billion joint yen intervention to stabilize the currency. Concurrently, oil prices fell 5% on geopolitical developments, while AstraZeneca shares dipped amid p
US stocks hit record highs as Iran talks reduced oil prices by 5%, while Bristol Myers Squibb and AstraZeneca began merger talks potentially forming a $400 billion drugmaker.
Financial Times reports AstraZeneca and Bristol Myers Squibb are exploring a potential $400 billion merger to create a top global pharmaceutical group. Recent strong sales in oncology and rare disease
AstraZeneca CEO Pascal Soriot urges Western pharma to accelerate innovation against Chinese rivals, likening the challenge to the automotive industry's EV shift. Despite a recent trial failure, the co
AstraZeneca shares fell 10% after its nerve drug Wainua failed a Phase III heart disease trial, erasing $20 billion in market value. Investors now await results from key oncology trials SERENA-4 and A
The FTSE 100 fell 0.6% amid Middle East tensions, dragged down by AstraZeneca after its nerve disease drug failed a late-stage trial. Oil prices rose marginally following U.S. strikes on Iran, impacti
European stocks rose led by tech rebounds, while crude oil dipped amid Middle East tensions. AstraZeneca shares fell 8% after its nerve disease drug Wainua failed late-stage cardiovascular trials.
AstraZeneca and Daiichi Sankyo are nearing a pricing agreement with UK regulators for their breast cancer drug Enhertu following a previous coverage denial. Talks aim to secure reimbursement access wh
C&EN releases its annual Global Top 50 chemical firms ranking ahead of schedule, alongside coverage of Anthropic's new science tool and AstraZeneca's renewed collaboration with CSPC.
London's FTSE 100 gained 0.5% led by healthcare and beverage stocks, highlighted by AstraZeneca's $1.77 billion drug deal and Genel Energy's acquisition of Capricorn Energy, as investors monitor US ec
Atinary Technologies and Radical AI deploy AI-driven labs to automate chemical reactions and material discovery, attracting investment and interest from firms like AstraZeneca. This shift aims to sign
GlaxoSmithKline agreed to acquire Nuvalent for approximately $11 billion to expand its oncology pipeline with two late-stage lung cancer treatments. The move aims to counter patent cliffs on HIV drugs
Northern UK universities partner with NHS trusts to create health innovation hubs, attracting medtech firms like Convatec despite AstraZeneca halting vaccine plant investment due to funding cuts.
The FTSE 100 closed 0.1% lower, weighed down by energy giants Shell and BP tracking crude oil weakness, while AstraZeneca shares dropped 3.1% following an FDA advisory panel vote against its experimen
The FDA seeks input to expand an AI-driven pilot program enabling real-time data submission for clinical trials, currently testing drugs for lymphoma and lung cancer with partners like AstraZeneca and
Oil and gas prices surged following reports of US plans to extend blockades on Iranian ports. AstraZeneca also announced a £300 million investment into UK life sciences.
AstraZeneca announced a £300m investment reversal in the UK, unfreezing paused projects in Cambridge and Macclesfield following a UK-US drug pricing deal. The announcement coincided with strong quarte
Prime Minister Keir Starmer announced AstraZeneca will invest £300 million ($405 million) in UK life sciences following a new US-UK pricing agreement. This investment secures 1,000 jobs in Macclesfiel
UK shares declined as traders digested mixed corporate earnings, with pharmaceutical giants AstraZeneca and GSK falling despite strong profit forecasts amidst geopolitical tensions.
AstraZeneca has agreed to pay CSPC Pharmaceutical Group up to $18.5 billion for eight drug development programs targeting weight loss and Type 2 diabetes, including a $1.2 billion upfront payment.
ChemBrief